A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Trial Identifier: D3254C00001
Sponsor: AstraZeneca
NCTID:: NCT04191304
Start Date: July 2020
Primary Completion Date: May 2024
Study Completion Date: November 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Innsbruck, AT, 6020
BE Brussels, BE, 1070
BE Edegem, BE, 2650
BE Leuven, BE, 3000
CH Bern, CH, 3010
CH Zürich, CH, 8091
DE Hannover, DE, 30625
DE Kirchheim, DE, 73230
DE Mannheim, DE, 68167
DK København Ø, DK, 2100
ES Salamanca, ES, 37007
ES Santander, ES, 39010
FR LILLE CEDEX, FR, 59037
FR PARIS Cedex 12, FR, 75571
FR PESSAC, FR, 33604
FR Strasbourg, FR, 67091
FR Suresnes Cedex, FR, 92151
FR Toulouse Cedex 9, FR, 31059
GB London, GB, W2 1NY
IL Haifa, IL, 34362
IL Holon, IL, 58100
IL Jerusalem, IL, 91120
IL Kfar Saba, IL, 44218
IL Petah Tiqva, IL, 49100
IL Ramat Gan, IL, 5265601
IL Rehovot, IL, 76100
IL Tel-Aviv, IL, 64239
IN Ahmedabad, IN, 380013
IN Ajmer, IN, 305001
IN Delhi, IN, 110029
IN Nagpur, IN, 440012
IT Bologna, IT, 40138
IT Milano, IT, 20132
JP Bunkyo-ku, JP, 113-8431
JP Chiba-shi, JP, 260-0852
JP Hamamatsu-shi, JP, 431-3192
JP Ichikawa-shi, JP, 272-8516
JP Kawasaki-shi, JP, 211-8510
JP Nishinomiya-shi, JP, 663-8501
JP Osaka-shi, JP, 530-8480
JP Sendai-shi, JP, 980-8574
KR Seoul, KR, 5505
NL Rotterdam, NL, 3015 GD
PL Chęciny, PL, 26-060
PL Gdańsk, PL, 80-214
PL Łódź, PL, 90-153
US, CA La Jolla, CA, US, 92037
US, CA Newport Beach, CA, US, 92663
US, GA Atlanta, GA, US, 30324
US, MD Bethesda, MD, US, 20892
US, MI Ann Arbor, MI, US, 48105
US, MN Rochester, MN, US, 55905-0001
US, NC Durham, NC, US, 27705
US, OH Cleveland, OH, US, 44106
US, OH Columbus, OH, US, 43212
US, UT Salt Lake City, UT, US, 84112
US, UT Salt Lake City, UT, US, 84107
US, WA Seattle, WA, US, 98115
US, WI Milwaukee, WI, US, 53226